Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy

Minerva Endocrinologica

Volumn 39, Issue 4, 2014, Pages 305-311

  Cancarini, A ^a   Costagliola, C ^b   Dell'omo, R ^b   Romano, M R ^b   Morescalchi, F ^a   Agnifili, L ^d   Ruggeri, G ^c   Semeraro, F ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c SPEDALI CIVILI   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bevacizumab; Diabetes mellitus; Erythropoietin; Vascular endothelial growth factor A

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN; VASCULOTROPIN; EPO PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AQUEOUS HUMOR; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PROLIFERATIVE RETINOPATHY; PROSPECTIVE STUDY; RETINA MACULA HOLE; VITRECTOMY; VITREOUS BODY; AGED; BODY FLUID COMPARTMENT; CHEMISTRY; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; METABOLISM; RETINAL PERFORATIONS; SECRETION (PROCESS); SERUM; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS HEMORRHAGE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; BODY FLUID COMPARTMENTS; COMORBIDITY; DIABETIC RETINOPATHY; ERYTHROPOIETIN; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL PERFORATIONS; SERUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 84922480283     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today JAMA 2003, 290 2057-60
2. Semeraro F, Parrinello G, Cancarini A, Pasquini L, Zarra E, Cimino A et al. Predicting the risk of diabetic retinopathy in type 2 diabetic patients J Diabetes Complications 2011.25 292-7
3. Boulton M, Foreman D, Williams G, McLeod D. VEFG localisation in diabetic retinopathy. Br J Ophthalmol 1998;82 561-8
4. Hernandez C, Fonollosa A, Garcia-Ramirez M, Higuera M, Catalan R, Miralles A et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular oedema Diabetes Care 2006,29 2028-33
5. Katsura Y, Okano T, Matsuno K, Osako M, Kure M, Watanabe T et al. Erythropoietin is higly elevated in vitreous fluid of patient with proliferative retinopathy Diabetes Care 2005,28 2252-4
6. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy N Engl Y Med 2005,353:782-92
7. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-47.
8. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999:274:23463-7
9. Erslev AJ. Erythropoietin NEngl J Med 1991:324:1339-44.
10. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice J Clin Invest 2008:118 526-33
11. Garcia-Ramirez M, Hernandez C, Simo R. Expression of erythropoietin and its receptor in the human retina a comparative study of diabetic and non diabetic subjects. Diabetes Care 2008,31 1189-94
12. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuch KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002,64:326-33.
13. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999:93.2627-36
14. Becerra SP, Amaral J. Erythropoietin an endogenous retinal survival factor. N Engl J Med 2002,347:1968-70.
15. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt 1 and mitochondrial modulation of cysteine proteases Circulation 2002;106:2973-9.
16. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades Nature 2001,412 641-7
17. Walshe TE, D'Amore PA. The role of hypoxia in vascular injury and repair Annual Rev Pathol 2008,3 615-43
18. Semenza GL. Regulation of Erythropoietin production New insights into molecular mechanism of oxygen homeostasis Hematol Oncol Clin North Am 1994,8 863-84.
19. Stahl A, Buchwald A, Martin G, Junker B, Chen J, Hansen LL et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina 2010,30:1524-9.
20. Friedman EA, L'Esperance FA, Brown CD, Barman DH. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease Kidney In Suppl 2003,87 S57-S63
21. Liu J, Narasimham P, Song YS, Nishi T, Yu F, Lee YS et al. Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress. Glia 2006,53:360-5
22. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Reina M, Vilarò S, Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003,18 2538-44
23. Wang ZY, Shen LJ, Tu L, Hu DN, Liu GY, Zhou ZL et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage Free Radic Biol Med 2009;46 1032-41
24. Fisher JW. Landmark advances in the development of erythropoietin Exp Biol Med 2010;235:1398-411.
25. Sekiguchi N, Inoguchi T, Kobayashi K, Sonoda N, Nawata H. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005:334:218-22
26. Grant MB, Boulton ME, Ljubimov AV. Erythropoietin. when liability becomes asset in neurovascular repair. J Clin Invest 2008,118.467-70
27. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity Arch Ophthalmol 1996,114 1219-28
28. Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophtalmol Vis Sci 2008,49.732-42
29. Costagliola C, Daniele A, dell'Omo R, Romano MR, Aceto F, Agnifili L et al. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res 2013,110 50-4.
30. Rinaldi M, Chiosi F, dell'Omo R, Romano MR, Parmeggiani F, Semeraro F et al. Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study Br J Clin Pharmacol 2012;74:940-6.
31. Rondon IT, MacMillan LA, Beckman BS, Goldberg MA, Schneider T, Bunn HF et al. Hypoxia up-regulates the activity of a novel erythropoietin mRNA binding protein J Biol Chem 1991,266 16594-8
32. dell'Omo R, Semeraro F, Bamonte G, Cifariello F, Romano MR, Costagliola C. Vitreous mediators in retinal hypoxic diseases Mediators Inflamm 2013,935301
33. Sun XM, Zhang YX. Effects of glucose on growth, metabolism and EPO expression in recombinant CHO cells cultures Sheng Wu Gong Cheng Xue Bao 2001;17:698-702.
34. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra et al. Erythropoietin administration protects retinal neurone from acute ischemia-reperfusion injury Proc Natl Acad Sci USA 2002;99 10659-64
35. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy Proc Natl Acad Sci USA 2004,101 823-8.
36. Lipton SA. Erythropoyetin for neurologic protection and diabetic neuropathy N Engl J Med 2004, 350 2516-7